Monoclonal antibodies targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), collectively referred to as immune checkpoint inhibitors (ICIs), have revolutionized the treatment of solid tumors but have also demonstrated efficacy in hematologic malignancies, including T-cell lymphomas. The gene discussed is CD274; the disease is T-cell non-Hodgkin lymphoma.